Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes
- PMID: 28402770
- DOI: 10.1056/NEJMoa1608664
Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes
Abstract
Background: Long-term trends in excess risk of death and cardiovascular outcomes have not been extensively studied in persons with type 1 diabetes or type 2 diabetes.
Methods: We included patients registered in the Swedish National Diabetes Register from 1998 through 2012 and followed them through 2014. Trends in deaths and cardiovascular events were estimated with Cox regression and standardized incidence rates. For each patient, controls who were matched for age, sex, and county were randomly selected from the general population.
Results: Among patients with type 1 diabetes, absolute changes during the study period in the incidence rates of sentinel outcomes per 10,000 person-years were as follows: death from any cause, -31.4 (95% confidence interval [CI], -56.1 to -6.7); death from cardiovascular disease, -26.0 (95% CI, -42.6 to -9.4); death from coronary heart disease, -21.7 (95% CI, -37.1 to -6.4); and hospitalization for cardiovascular disease, -45.7 (95% CI, -71.4 to -20.1). Absolute changes per 10,000 person-years among patients with type 2 diabetes were as follows: death from any cause, -69.6 (95% CI, -95.9 to -43.2); death from cardiovascular disease, -110.0 (95% CI, -128.9 to -91.1); death from coronary heart disease, -91.9 (95% CI, -108.9 to -75.0); and hospitalization for cardiovascular disease, -203.6 (95% CI, -230.9 to -176.3). Patients with type 1 diabetes had roughly 40% greater reduction in cardiovascular outcomes than controls, and patients with type 2 diabetes had roughly 20% greater reduction than controls. Reductions in fatal outcomes were similar in patients with type 1 diabetes and controls, whereas patients with type 2 diabetes had smaller reductions in fatal outcomes than controls.
Conclusions: In Sweden from 1998 through 2014, mortality and the incidence of cardiovascular outcomes declined substantially among persons with diabetes, although fatal outcomes declined less among those with type 2 diabetes than among controls. (Funded by the Swedish Association of Local Authorities and Regions and others.).
Comment in
-
Increase in the Incidence of Diabetes and Its Implications.N Engl J Med. 2017 Apr 13;376(15):1473-1474. doi: 10.1056/NEJMe1616575. N Engl J Med. 2017. PMID: 28402766 No abstract available.
-
Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes.N Engl J Med. 2017 Jul 20;377(3):300. doi: 10.1056/NEJMc1706292. N Engl J Med. 2017. PMID: 28727404 No abstract available.
Similar articles
-
Excess Mortality among Persons with Type 2 Diabetes.N Engl J Med. 2015 Oct 29;373(18):1720-32. doi: 10.1056/NEJMoa1504347. N Engl J Med. 2015. PMID: 26510021
-
Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study.Lancet. 2018 Aug 11;392(10146):477-486. doi: 10.1016/S0140-6736(18)31506-X. Epub 2018 Aug 9. Lancet. 2018. PMID: 30129464 Free PMC article.
-
Cardiovascular disease and mortality in patients with type 2 diabetes after bariatric surgery in Sweden: a nationwide, matched, observational cohort study.Lancet Diabetes Endocrinol. 2015 Nov;3(11):847-54. doi: 10.1016/S2213-8587(15)00334-4. Epub 2015 Sep 28. Lancet Diabetes Endocrinol. 2015. PMID: 26429401
-
Effects of glucose-lowering and multifactorial interventions on cardiovascular and mortality outcomes: a meta-analysis of randomized control trials.Diabet Med. 2016 Mar;33(3):280-9. doi: 10.1111/dme.12885. Epub 2015 Sep 8. Diabet Med. 2016. PMID: 26282461 Review.
-
The relationship of vitamin D status to risk of cardiovascular disease and mortality.Dan Med J. 2015 Feb;62(2):B5008. Dan Med J. 2015. PMID: 25634511 Review.
Cited by
-
Moderating effect for illness uncertainty on the relationship of depressive and anxiety symptoms among patients with type 1 diabetes in Taif region, Saudi Arabia.J Family Med Prim Care. 2024 Sep;13(9):3576-3589. doi: 10.4103/jfmpc.jfmpc_1661_23. Epub 2024 Sep 11. J Family Med Prim Care. 2024. PMID: 39464983 Free PMC article.
-
The Comparison of the Effectiveness of Dapagliflozin and Empagliflozin in the Prevention of Cardiovascular Outcomes in Patients With Type 2 Diabetes: A Network Meta-Analysis.Cureus. 2024 Sep 19;16(9):e69711. doi: 10.7759/cureus.69711. eCollection 2024 Sep. Cureus. 2024. PMID: 39429324 Free PMC article. Review.
-
Sodium-Glucose Co-transporter-2 Inhibitors in Type 1 Diabetes Mellitus: The Framework for Recommendations for Their Potential Use.Diabetes Ther. 2024 Dec;15(12):2445-2453. doi: 10.1007/s13300-024-01657-9. Epub 2024 Oct 16. Diabetes Ther. 2024. PMID: 39412607 Free PMC article.
-
Modern Challenges in Type 2 Diabetes: Balancing New Medications with Multifactorial Care.Biomedicines. 2024 Sep 7;12(9):2039. doi: 10.3390/biomedicines12092039. Biomedicines. 2024. PMID: 39335551 Free PMC article. Review.
-
Association of plasma endothelin-1 levels with revascularization strategies and short-term clinical outcomes: Role of diabetes.Heliyon. 2024 Sep 11;10(18):e37777. doi: 10.1016/j.heliyon.2024.e37777. eCollection 2024 Sep 30. Heliyon. 2024. PMID: 39315138 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical